STOCK TITAN

[Form 4] Myomo Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Myomo, Inc. director Thomas F. Kirk reported an open-market purchase of 50,000 shares of Myomo common stock on 08/25/2025 at an execution price of $1.15 per share. After the transaction the reporting person beneficially owns 474,420 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/26/2025. The filing states the purchases occurred in multiple lots at $1.15 per share and that the reporting party will provide transaction details to the SEC upon request. No derivative transactions, dispositions, or additional securities classes are reported.

Il direttore di Myomo, Inc., Thomas F. Kirk, ha comunicato un acquisto sul mercato aperto di 50.000 azioni ordinarie Myomo in data 25/08/2025 a un prezzo di esecuzione di $1,15 per azione. Dopo l’operazione, la persona segnalante detiene beneficiariamente 474.420 azioni, possedute direttamente. Il Modulo 4 è stato firmato da un procuratore il 26/08/2025. La comunicazione indica che gli acquisti sono avvenuti in più tranche a $1,15 per azione e che la parte segnalante fornirà i dettagli delle operazioni alla SEC su richiesta. Non sono segnalate transazioni in derivati, cessioni né altre classi di titoli.

El director de Myomo, Inc., Thomas F. Kirk, informó una compra en el mercado abierto de 50.000 acciones ordinarias de Myomo el 25/08/2025 a un precio de ejecución de $1,15 por acción. Tras la operación, la persona informante posee beneficiariamente 474.420 acciones, mantenidas directamente. El Formulario 4 fue firmado por un apoderado el 26/08/2025. La presentación indica que las compras se realizaron en varios lotes a $1,15 por acción y que la parte informante facilitará los detalles de la transacción a la SEC si se lo solicitan. No se reportan transacciones de derivados, disposiciones ni otras clases de valores.

Myomo, Inc. 이사 Thomas F. Kirk는 2025-08-25에 공개 시장에서 Myomo 보통주 50,000주를 주당 $1.15에 매수했다고 보고했습니다. 거래 후 보고인은 직접 보유 중인 474,420주를 실질적으로 소유하고 있습니다. Form 4는 2025-08-26에 대리인이 서명했습니다. 제출서에는 매수가 여러 차례에 걸쳐 주당 $1.15에 이루어졌으며 요청 시 SEC에 거래 세부 정보를 제공하겠다고 되어 있습니다. 파생상품 거래, 처분 또는 다른 증권종류는 보고되지 않았습니다.

Thomas F. Kirk, administrateur de Myomo, Inc., a déclaré un achat sur le marché libre de 50 000 actions ordinaires Myomo le 25/08/2025 à un prix d’exécution de 1,15 $ par action. Après la transaction, la personne déclarante détient à titre bénéficiaire 474 420 actions, détenues directement. Le formulaire 4 a été signé par un mandataire le 26/08/2025. Le dépôt indique que les achats ont été effectués en plusieurs lots à 1,15 $ par action et que la partie déclarante fournira les détails des transactions à la SEC sur demande. Aucune opération sur dérivés, cession ou autre classe de titres n’est signalée.

Thomas F. Kirk, Direktor von Myomo, Inc., meldete am 25.08.2025 einen Kauf von 50.000 Myomo-Stammaktien im offenen Markt zu einem Ausführungspreis von $1,15 pro Aktie. Nach der Transaktion besitzt die meldende Person wirtschaftlich 474.420 Aktien, die direkt gehalten werden. Das Formular 4 wurde am 26.08.2025 von einem Bevollmächtigten unterschrieben. Die Einreichung gibt an, dass die Käufe in mehreren Tranchen zu jeweils $1,15 pro Aktie erfolgten und die meldende Partei auf Anfrage der SEC Transaktionsdetails zur Verfügung stellen wird. Es werden keine Derivatgeschäfte, Veräußerungen oder weitere Wertpapierklassen gemeldet.

Positive
  • Director open-market purchase of 50,000 shares shows insider acquisition and increased direct ownership to 474,420 shares.
  • Clear disclosure of transaction date, price ($1.15) and that purchases were executed in multiple lots; attorney-in-fact signature provided.
Negative
  • None.

Insights

TL;DR: A director bought 50,000 shares at $1.15, increasing direct holdings to 474,420 shares; the trade is disclosed via Form 4.

The open-market purchase by a director is a straightforward insider acquisition disclosed under Section 16. The size—50,000 shares—is material relative to the director's total direct holding disclosed here, raising his direct stake to 474,420 shares. The reported execution price of $1.15 per share and the statement that purchases occurred in multiple lots are explicitly documented. This Form 4 contains no information about motives, funding source, or planned future transactions, so market-impact conclusions cannot be drawn from the filing alone.

TL;DR: Director timely reported open-market purchases; disclosure appears complete for the non-derivative transaction listed.

The filing satisfies basic Section 16 reporting: it identifies the reporting person as a director, lists the transaction date, transaction code (P for open-market purchase), amount, price, and post-transaction beneficial ownership. The explanation clarifies multiple-lot purchases at $1.15 and offers to provide lot-level details to the SEC on request. There are no indications of Rule 10b5-1 plan usage or coordinated filings. For governance review, the disclosure is routine and compliant based on the provided content.

Il direttore di Myomo, Inc., Thomas F. Kirk, ha comunicato un acquisto sul mercato aperto di 50.000 azioni ordinarie Myomo in data 25/08/2025 a un prezzo di esecuzione di $1,15 per azione. Dopo l’operazione, la persona segnalante detiene beneficiariamente 474.420 azioni, possedute direttamente. Il Modulo 4 è stato firmato da un procuratore il 26/08/2025. La comunicazione indica che gli acquisti sono avvenuti in più tranche a $1,15 per azione e che la parte segnalante fornirà i dettagli delle operazioni alla SEC su richiesta. Non sono segnalate transazioni in derivati, cessioni né altre classi di titoli.

El director de Myomo, Inc., Thomas F. Kirk, informó una compra en el mercado abierto de 50.000 acciones ordinarias de Myomo el 25/08/2025 a un precio de ejecución de $1,15 por acción. Tras la operación, la persona informante posee beneficiariamente 474.420 acciones, mantenidas directamente. El Formulario 4 fue firmado por un apoderado el 26/08/2025. La presentación indica que las compras se realizaron en varios lotes a $1,15 por acción y que la parte informante facilitará los detalles de la transacción a la SEC si se lo solicitan. No se reportan transacciones de derivados, disposiciones ni otras clases de valores.

Myomo, Inc. 이사 Thomas F. Kirk는 2025-08-25에 공개 시장에서 Myomo 보통주 50,000주를 주당 $1.15에 매수했다고 보고했습니다. 거래 후 보고인은 직접 보유 중인 474,420주를 실질적으로 소유하고 있습니다. Form 4는 2025-08-26에 대리인이 서명했습니다. 제출서에는 매수가 여러 차례에 걸쳐 주당 $1.15에 이루어졌으며 요청 시 SEC에 거래 세부 정보를 제공하겠다고 되어 있습니다. 파생상품 거래, 처분 또는 다른 증권종류는 보고되지 않았습니다.

Thomas F. Kirk, administrateur de Myomo, Inc., a déclaré un achat sur le marché libre de 50 000 actions ordinaires Myomo le 25/08/2025 à un prix d’exécution de 1,15 $ par action. Après la transaction, la personne déclarante détient à titre bénéficiaire 474 420 actions, détenues directement. Le formulaire 4 a été signé par un mandataire le 26/08/2025. Le dépôt indique que les achats ont été effectués en plusieurs lots à 1,15 $ par action et que la partie déclarante fournira les détails des transactions à la SEC sur demande. Aucune opération sur dérivés, cession ou autre classe de titres n’est signalée.

Thomas F. Kirk, Direktor von Myomo, Inc., meldete am 25.08.2025 einen Kauf von 50.000 Myomo-Stammaktien im offenen Markt zu einem Ausführungspreis von $1,15 pro Aktie. Nach der Transaktion besitzt die meldende Person wirtschaftlich 474.420 Aktien, die direkt gehalten werden. Das Formular 4 wurde am 26.08.2025 von einem Bevollmächtigten unterschrieben. Die Einreichung gibt an, dass die Käufe in mehreren Tranchen zu jeweils $1,15 pro Aktie erfolgten und die meldende Partei auf Anfrage der SEC Transaktionsdetails zur Verfügung stellen wird. Es werden keine Derivatgeschäfte, Veräußerungen oder weitere Wertpapierklassen gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KIRK THOMAS F

(Last) (First) (Middle)
C/O MYOMO, INC.
45 BLUE SKY DR., SUITE 101

(Street)
BURLINGTON MA 01803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/25/2025 P 50,000(1) A $1.15(2) 474,420 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents open market purchases.
2. Shares were purchased in multiple lots, each executing at $1.15 per share. Reporting Party agrees to provide details of the transactions to the SEC upon request.
/s/ David A. Henry, Attorney-in-Fact 08/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Myomo (MYO) disclose on Form 4?

Director Thomas F. Kirk reported an open-market purchase of 50,000 shares on 08/25/2025 at $1.15 per share.

How many Myomo shares does the reporting director own after the transaction?

The reporting person beneficially owns 474,420 shares of Myomo common stock following the reported purchase.

Was the Form 4 transaction a purchase or sale and what transaction code was used?

The transaction was an open-market purchase and is reported with transaction code P.

Does the filing indicate the price(s) paid for the shares?

Yes. The filing states the shares were purchased in multiple lots, each executing at $1.15 per share.

Who signed the Form 4 for the reporting person?

The Form 4 is signed by David A. Henry, Attorney-in-Fact on 08/26/2025.
Myomo

NYSE:MYO

MYO Rankings

MYO Latest News

MYO Latest SEC Filings

MYO Stock Data

42.34M
32.31M
6.88%
66.28%
4.11%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BOSTON